UNSPSC 42294514: Hemostatic eraser probes

In this classification, this commodity indicates a product used as a hemostatic eraser probe during a surgical procedure in a medical setting. US FDA regulates Hemostatic eraser probes under 21 CFR 886.4115 and under FDA product code HQO. Most nations, for tariff and trade purposes, schedule these products under HS 901850.

UNSPSC 42294514 Hemostatic eraser probes is a Commodity code showing minimal alignment with recent state and local procurement activity. The code nominally describes medical instruments for hemostasis control, yet the recent opportunities tagged under it span fiber-splicing services, handheld retinal screening devices, general medical supplies through cooperative purchasing, physical health products, and law enforcement equipment. None of these categories match the scope of hemostatic erasers or their typical clinical application. The issuing bodies are diverse—a rural electric cooperative, state health agencies coordinating through NASPO ValuePoint, a county public hospital system, and Minnesota-based cooperative purchasing vehicles—but the actual work being solicited bears no coherent relationship to the code's nominal commodity.

The geographic spread across recent opportunities includes Florida, Idaho, California, Minnesota, and Washington, yet this geographic diversity reflects tagging misalignment rather than true market activity for hemostatic eraser probes. No solicitation in the block describes procurement of hemostatic instruments or related supplies. Suwannee Valley Electric Cooperative's October 2026 fiber-splicing RFP (due November 13, 2026) and San Mateo Medical Center's October 2026 handheld retinal screening device RFP (due November 6, 2026) exemplify the disconnect—neither involves the hemostatic product or service family. The code reports little relevant recent state and local procurement activity, and the opportunities present suggest a data tagging error rather than active demand for the commodity itself.